ROCHE INVIRASE COMBINED WITH NUCLEOSIDES SHOWS GREATER SURROGATE MARKER ACTIVITY IN AZT-NAIVE PATIENTS; CONFIRMATORY TRIALS MAY NEED MORE PATIENTS
Executive Summary
Roche's Invirase, when used in combination with nucleoside analogs, has a greater positive effect on HIV surrogate markers in patients who have received no prior treatment with Glaxo Wellcome's Retrovir (zidovudine, AZT) than in those who have.